[Treatment of neurocysticercosis with praziquantel].
Twenty seven patients with neurocysticercosis were treated with praziquantel in progressive doses reaching 50 mg/kg/day associated with dexamethasone for 21 days. The patients were followed during and after treatment and those followed up for one year repeated their immunological tests (indirect immunofluorescence and ELISA) at this time. Headache was the most frequent symptom during the treatment, occurring on 37% of patients. During the treatment 18.5% of patients had intracranial hypertension and one died. One year after treatment 72.2% of patients who finished treatment improved. The immunological tests became negative in 45.4% of patients sera and 42.8% of cerebrospinal fluids. There was no correlation between the clinical evolution and immunological tests. In this study it is not possible to affirm that both negative immunological tests and good clinical evolution were consequent to the efficacy of praziquantel treatment. Due to the great frequency and seriousness of this treatment complications, the patients with neurocysticercosis must be individually evaluated to know the risks and the benefits of the treatment with praziquantel.
Vianna
L G
LG
Universidade de Brasília, Brasil.
Macedo
V
V
Mello
P
P
Souza
H A
HA
Costa
J M
JM
D000293:Adolescent; D000328:Adult; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D003551:Cysticercosis / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis
D011223:Praziquantel; D003907:Dexamethasone
Tratamento da neurocisticercose com praziquantel.